<DOC>
	<DOCNO>NCT00504231</DOCNO>
	<brief_summary>This randomize trial compare immunogenicity 60 % dose intradermal ( ID ) influenza vaccination standard intramuscular ( IM ) vaccination full-dose 60 % dose vaccine . Pre- postvaccination measurement hemagglutination inhibition antibody ( HAI ) titer compare . Participants receive reduced-dose vaccine revaccinated full-dose IM vaccine .</brief_summary>
	<brief_title>Intradermal Influenza Vaccine Study Elders</brief_title>
	<detailed_description>This study open-label randomize trial consist community-dwelling adult 65 year old living Puget Sound area Washington State . Subjects enrol randomly assign receive license , 2007-2008 Northern Hemisphere TIV vaccine ( Fluzone , lot U2440AA ; Sanofi Pasteur ) contain concentration hemagglutinin A/Solomon Islands/3/2006 ( A/H1N1 ) , A/Wisconsin/67/2005 ( A/H3N2 ) , B/Malaysia/2506/2004 ( B ) : 15 ug/0.5 mL IM route , 9 ug/0.3 mL ID IM route , 4.5 ug/0.15 mL give twice ID route nondominant arm . A block randomization scheme ( 1:1:1:1 ) , stratify sex , use . For IM vaccination , 0.3 mL 0.5 mL vaccine remove multidose ( 5 mL ) vial 25-gauge , 1-inch detachable needle ( Becton Dickinson ) inject deltoid muscle 90 degree angle skin . For ID vaccination , 0.3 mL 0.15 mL drawn TB syringe 25-gauge , 5/8-inch needle ( Terumo Medical ) . The needle insert 15 degree angle skin overlie deltoid arm . The vaccine slowly inject material expel induration appear . Subjects randomize 0.15-mL group receive 2 side-by-side ID injection 3 cm apart . Participants return 4 week determine postvaccination antibody titer . At follow-up visit , assign reduce dose IM ID influenza vaccination receive full-dose IM influenza vaccination . These participant return another 4 week repeat HAI titer . A nonrandomized subset subject ( base availability willingness participate ) return 14 day initial vaccination T cell assay exploratory substudy examine cellular immune response .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Ambulatory , medically stable person 65 year age older Able read understand inform consent Available trial period followup Able understand comply plan study procedure Able contact telephone followup adverse event Known allergy eggs component vaccine ( i.e. , thimerosal ) History GuillainBarr√© Syndrome ( GBS ) Has confirm suspect immunodeficient immunosuppressive condition ( include congenital acquire immunosuppressive therapy , human immunodeficiency virus [ HIV ] ) Endstage renal disease require hemodialysis Active neoplastic disease history hematologic malignancy ( except localize skin prostate cancer stable absence therapy ) Acute chronic condition ( opinion investigator ) would render vaccination unsafe would interfere evaluation response ( include limit following : know chronic liver disease , significant renal disease , oxygendependent chronic lung disease , New York Heart Association Functional Class III IV , unstable progressive neurologic disorder , insulin control diabetes mellitus ) Use experimental vaccine within month prior study entry , expect use experimental license vaccine blood/blood product duration study . Receipt immunoglobulin blood product within 3 month prior enrollment Receipt license vaccine within precede 4 week History severe reaction follow influenza vaccination Current plan participation research study investigational drug . Participation research study involve use license drug , either approve investigational indication , permit approval PI , participation research study involve vaccine medication . Current use previous chronic administration , define &gt; 14 day previous six month , immunosuppressant immunemodifying drug . ( For oral injected corticosteroid , immunemodifying dose define prednisone equivalent &gt; 10 mg/day &gt; 800mcg per day inhale beclomethasone dipropionate equivalent ) . Topical steroid allow . Use cytotoxic therapy previous 2 year . Plans receive cytotoxic therapy study period . Concurrent moderate severe illness . Need defer vaccination recovery . ( Vaccination contraindicate subject mild illness lowgrade fever ) .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>influenza</keyword>
	<keyword>prevention</keyword>
	<keyword>intradermal</keyword>
	<keyword>vaccine</keyword>
	<keyword>delivery</keyword>
	<keyword>elderly</keyword>
</DOC>